Protagonist Therapeutics Inc (NASDAQ: PTGX) is 18.65% higher on its value in year-to-date trading and has touched a low of $24.22 and a high of $60.60 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The PTGX stock was last observed hovering at around $46.95 in the last trading session, with the day’s loss setting it -1.15%.
Currently trading at $45.80, the stock is -2.58% and 3.26% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.33 million and changing -2.45% at the moment leaves the stock 8.72% off its SMA200. PTGX registered 72.31% gain for a year compared to 6-month gain of -1.19%. The firm has a 50-day simple moving average (SMA 50) of $44.356 and a 200-day simple moving average (SMA200) of $42.1253.
The stock witnessed a -15.99% loss in the last 1 month and extending the period to 3 months gives it a 20.72%, and is 7.59% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.15% over the week and 5.44% over the month.
Protagonist Therapeutics Inc (PTGX) has around 126 employees, a market worth around $2.81B and $434.43M in sales. Current P/E ratio is 10.89. Profit margin for the company is 63.34%. Distance from 52-week low is 89.10% and -24.42% from its 52-week high. The company has generated returns on investments over the last 12 months (40.14%).
The EPS is expected to shrink by -130.94% this year
337.0 institutions hold shares in Protagonist Therapeutics Inc (PTGX), with institutional investors hold 110.46% of the company’s shares. The shares outstanding are 61.04M, and float is at 57.88M with Short Float at 8.13%. Institutions hold 108.94% of the Float.
The top institutional shareholder in the company is FARALLON CAPITAL MANAGEMENT LLC with over 5.84 million shares valued at $202.38 million. The investor’s holdings represent 9.5274 of the PTGX Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 5.76 million shares valued at $199.52 million to account for 9.3925 of the shares outstanding. The other top investors are RTW INVESTMENTS, LP which holds 5.29 million shares representing 8.6231 and valued at over $183.17 million, while BVF INC/IL holds 5.4144 of the shares totaling 3.32 million with a market value of $115.01 million.
Protagonist Therapeutics Inc (PTGX) Insider Activity
The most recent transaction is an insider sale by Waddill William D., the company’s Director. SEC filings show that Waddill William D. sold 4,000 shares of the company’s common stock on Mar 17 ’25 at a price of $54.25 per share for a total of $0.22 million. Following the sale, the insider now owns 13130.0 shares.
Still, SEC filings show that on Mar 13 ’25, MOLINA ARTURO MD (Chief Medical Officer) disposed off 30,514 shares at an average price of $55.74 for $1.7 million. The insider now directly holds 83,892 shares of Protagonist Therapeutics Inc (PTGX).
